Axxam

Anna Mondini, our Head of Electrophysiology, and Manuel Arcangeletti, Scientist in Electrophysiology, will be attending the EU Nanion User Meeting in Munich, Germany!   This prestigious annual event, organized by Nanion Technologies, is a key gathering for experts in electrophysiology and ion channel research. It’s a fantastic opportunity to exchange insights on cutting-edge technologies like automated patch clamp, cell-based assays and drug screening.   🗓️ Date: 22-23 October 📍 Location: Munich, Germany Stay tuned for updates from the event! #Electrophysiology #IonChannelResearch #PatchClamp #ScientificInnovation #DrugDiscovery #Conference

Meet Tom Grammatopoulos, PhD, our Senior Director of BD North America, at the Ion Channel Modulation Symposium (ICMS) in Boston! ✨   Organized by Sophion Bioscience, this annual event brings together leading minds in ion channel research from academia, CROs and pharma to discuss groundbreaking advancements in ion channel modulation, a key area for drug discovery and therapeutic innovation.   Don't miss the opportunity to connect with Tom and explore how ion channels are shaping the future of science! 🌟   📅 October 23-24 📍 Boston, MA   #ICMS #DrugDiscovery #IonChannels #Pharma #Conference

What an amazing experience being part of the Scientific Committee for the 7th #BraYn Conference 2024 in #Verona, which concluded last Friday!    It was a privilege to help bringing together such a unique event where young researchers, PhD candidates, and postdocs have the incredible opportunity to meet renowned experts, including Nobel laureates #MartinChalfie   Thank you to everyone who participated and shared their insights!   Looking forward to continuing the collaborations and breakthroughs that emerged during the conference. See you all for the next edition!!   #BraYnConference2024 #BrainResearch #InnovationInScience #DrugDiscovery Axxam

📢 A big thank you to everyone who attended our Boot Camp Webinar: "Drug Discovery for Metabolic Disorders – More than Gut Feeling"   It was an engaging session and we’re grateful for the insightful discussions led by our brilliant speakers Joerg Hueser, our CSO, and Alberto Di Silvio, Head of Compound Profiling.   We explored:   ✅ Incretin mimetics for the treatment of metabolic disorders ✅Axxam’s bioassays and compound libraries supporting metabolism drug discovery research ✅Pharmacological compound profiling at Axxam   If you missed it, don’t worry! Stay tuned for more events and resources: https://lnkd.in/dhH7Vdkk Or contact us: https://lnkd.in/d3z3gVNy   #MetabolicDisorders #CompoundProfiling #CompoundLibrary #DrugDiscovery #Innovation #Webinar

Harnessing the power of generative AI for drug discovery!   At Axxam we are designing a focused library of inhibitors targeting protein-protein interactions (PPI): #AXXPPI!   Our goal is to create molecules that not only meet the specific requirements for disrupting PPIs but also possess superior physicochemical properties paving the way for hits with higher chance to become candidates.   ~1.000 molecules are ready to be screened!   👉 Download and read Dario Gioia poster, presented at the #EFMC, to know more about how we are creating our library. #PPI #ScreeningCollection #ScreeningSolutions #CompoundLibrary #DrugDiscovery

🌺 Axxam Goes Pink for Breast Cancer Awareness Month 🌺   In recognition of Breast Cancer Awareness Month, the "XX" of our company logo has become pink.    At Axxam, we believe in the power of science and innovation to improve lives. This October, we join the global community in recognizing the importance of early detection, research, and care in the fight against breast cancer.   Together, we can make a difference. 🤝    #BreastCancerAwareness #Axxam #ResearchMatters #PinkOctober #DrugDiscovery

🚀 Exciting Partnership Announcement!    Opertech Bio and AXXSense, a division of Axxam, are joining forces to drive innovation in taste and olfaction research!    This strategic collaboration brings together Opertech Bio’s breakthrough TāStation® taste evaluation platform with AXXSense’s cutting-edge expertise in discovering taste-modulating ingredients. By leveraging the strengths of both companies, we aim to deliver powerful solutions that will benefit product development across various industries.   Scott Horvitz, CEO of Opertech Bio, says it best: “We’re thrilled to partner with AXXSense. Together, we can accelerate the discovery of new taste solutions and bring value to our customers.”   👉Read the full press release: https://lnkd.in/dU5SSJgW   Stay tuned for what’s to come!    #Partnerships #Innovation #TasteTech #Biotech #OpertechBio #AXXSense

Biotech Summit in Austria starts today and together with our CSO Jörg Hüser we are looking forward to connect with delegates here in beautiful Innsbruck. #BSA24 #Axxam #Drug Discovery

Meet Tom Grammatopoulos, PhD, our Senior Director of BD for North America, at the Pharma Partnering US Summit 2024 in Boston!   Join Tom and other industry leaders on October 16-17 to explore opportunities in pharmaceutical business development, R&D collaborations and strategic alliances.   Connect with Tom to discuss how we're driving innovation in healthcare. Let’s partner for a healthier future! 🌐   📅 Date: October 16-17, 2024 📍 Location: Boston, MA   #PharmaSummit #BusinessDevelopment #Innovation #Networking #Pharma #LifeSciences #DrugDiscovery

🏆 We extend our congratulations to Victor Ambros and Gary Ruvkun for being awarded the 2024 Nobel Prize in Physiology or Medicine! Their groundbreaking work on microRNA has unlocked essential insights into gene regulation, transforming our understanding of how genes influence cellular development and function. ✳ At Axxam, we have expertise in the field of microRNAs and we can contribute developing tools to address microRNAs role in complex model systems and investigate their function at molecular and cellular levels. Let’s harness this momentum in microRNA research to create transformative solutions in health and medicine! 👉 For more insights into our RNA biology expertise, visit our page: https://lnkd.in/dq-v2Y48 #NobelPrize #MicroRNA #Genomics #DrugDiscovery #Axxam